The cholesterol of high-density lipoproteins (HDLs) and its major proteic component, apoA-I, have been widely investigated as potential predictors of acute cardiovascular (CV) events. In particular, HDL cholesterol levels were shown to be inversely and independently associated with the risk of acute CV diseases in different patient populations, including autoimmune and chronic inflammatory disorders. Some relevant and direct anti-inflammatory activities of HDL have been also recently identified targeting both immune and vascular cell subsets. These studies recently highlighted the improvement of HDL function (instead of circulating levels) as a promising treatment strategy to reduce inflammation and associated CV risk in several diseases, such as systemic lupus erythematosus and rheumatoid arthritis. In these diseases, anti-inflammatory treatments targeting HDL function might improve both disease activity and CV risk. In this narrative review, we will focus on the pathophysiological relevance of HDL and apoA-I levels/functions in different acute and chronic inflammatory pathophysiological conditions.

Impact of systemic inflammation and autoimmune diseases on apoA-i and HDL plasma levels and functions / F. Montecucco, E. Favari, G.D. Norata, N. Ronda, J. Nofer, N. Vuilleumier (HANDBOOK OF EXPERIMENTAL PHARMACOLOGY). - In: High Density Lipoproteins: from biological understanding to clinical exploitation / [a cura di] A. von Eckardstein, D. Kardassis. - New York : Springer, 2015. - ISBN 9783319096643. - pp. 455-482 [10.1007/978-3-319-09665-0_14]

Impact of systemic inflammation and autoimmune diseases on apoA-i and HDL plasma levels and functions

G.D. Norata;
2015

Abstract

The cholesterol of high-density lipoproteins (HDLs) and its major proteic component, apoA-I, have been widely investigated as potential predictors of acute cardiovascular (CV) events. In particular, HDL cholesterol levels were shown to be inversely and independently associated with the risk of acute CV diseases in different patient populations, including autoimmune and chronic inflammatory disorders. Some relevant and direct anti-inflammatory activities of HDL have been also recently identified targeting both immune and vascular cell subsets. These studies recently highlighted the improvement of HDL function (instead of circulating levels) as a promising treatment strategy to reduce inflammation and associated CV risk in several diseases, such as systemic lupus erythematosus and rheumatoid arthritis. In these diseases, anti-inflammatory treatments targeting HDL function might improve both disease activity and CV risk. In this narrative review, we will focus on the pathophysiological relevance of HDL and apoA-I levels/functions in different acute and chronic inflammatory pathophysiological conditions.
ApoA-I; Autoimmune disease; HDL; Innate immunity; Systemic inflammation
Settore BIO/14 - Farmacologia
2015
http://www.springer.com/series/164
Book Part (author)
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/274555
Citazioni
  • ???jsp.display-item.citation.pmc??? 16
  • Scopus 36
  • ???jsp.display-item.citation.isi??? 36
social impact